<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127525</url>
  </required_header>
  <id_info>
    <org_study_id>IRX-2021-001</org_study_id>
    <nct_id>NCT05127525</nct_id>
  </id_info>
  <brief_title>EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)</brief_title>
  <acronym>CLEAN</acronym>
  <official_title>Randomized, Double-Masked, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of IRX-101 Versus 5% Povidone-Iodine as an Ocular Surface Sterilizer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iRenix Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iRenix Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-masked, multicenter, study to evaluate the efficacy, safety, and&#xD;
      tolerability of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal&#xD;
      anti-VEGF injections. The study will be conducted in up to 30 centers in the United States&#xD;
      (US).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravitreal injection therapy (IVT) of anti-vascular endothelial growth factor (VEGF) agents&#xD;
      has transformed the treatment landscape of several retinal diseases, including exudative&#xD;
      (wet) macular degeneration, retinal vein occlusion, diabetic macular edema, and choroidal&#xD;
      neovascularization. The most common adverse effects of IVT occur due to the side effects of&#xD;
      Povidone-Iodine 5% (PI; brand name: Betadine® 5%; Alcon, Fort Worth, TX), the antiseptic&#xD;
      placed on the ocular surface prior to each injection. PI is nearly universally used to&#xD;
      prevent ocular infection (endophthalmitis). PI leads to marked corneal epithelial toxicity in&#xD;
      humans,6, 7 resulting in debilitating side effects including decreased visual acuity and pain&#xD;
      that can last more than 3 days post-IVT. Post-IVT pain is severe enough to require oral&#xD;
      analgesics in up to 30% of patients and is a frequent cause of treatment discontinuation.&#xD;
      Therefore, there is an unmet need in ophthalmology for a potent ocular antiseptic with a&#xD;
      superior safety profile.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of infectious endophthalmitis after topical use of IRX-101 combined with IVT</measure>
    <time_frame>2 hours post-injection</time_frame>
    <description>To evaluate the rate of infectious endophthalmitis after topical use of IRX-101 following intravitreal injection therapy (IVT) (% occurrence or rate of population randomized to IRX-101 test arm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Telephone questionnaire regarding patient-reported post-injection pain</measure>
    <time_frame>2 hours post-injection</time_frame>
    <description>Telephone questionnaire with questions asked of patients regarding patient-reported post-injection pain compared to Providone-Iodine Betadine control group (three questions asked scale of 0 to 10, 0 being no pain to 10 being worst pain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Branch Retinal Vein Occlusion</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Test Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IRX-101 drops instilled prior to intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Povidone-Iodine/Betadine drops instilled prior to intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IRX-101</intervention_name>
    <description>IRX-101 to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)</description>
    <arm_group_label>Test Drug</arm_group_label>
    <other_name>Test Arm 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Providone-Iodine Betadine to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Capable of giving informed consent&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, ≥ 18 years of age and receiving intravitreal anti-VEGF injections in&#xD;
             one or both eyes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or past diagnosis of endophthalmitis&#xD;
&#xD;
          2. Current diagnosis of uveitis&#xD;
&#xD;
          3. Current use of viscous lidocaine products for ocular anesthesia prior to IVT&#xD;
&#xD;
          4. Currently receiving intravitreal steroid injections&#xD;
&#xD;
          5. Concurrent participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Smith, MD, MS</last_name>
    <role>Study Chair</role>
    <affiliation>iRenix Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanessa Tasso, MA, MBA</last_name>
    <phone>9497517039</phone>
    <email>vanessa@irenix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Retina Associates of Florida, LLC</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609-4614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Appenzeller, MS</last_name>
      <phone>813-875-6373</phone>
      <email>retinahv@tampabay.rr.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

